Abstract：【Objective】To investigate the effect of postoperative chemotherapy combined with endocrine therapy on the advanced prostate cancer and the correlation of ERβ expression in cancer tissues.【Methods】A total of 120 patients with advanced prostate cancer were treated in our hospital from January 2015 to March 2017, and randomly divided into the experimental group and the control group, 60 cases in each group . The experimental group received chemotherapy and endocrine therapy, and the control group received routine chemotherapy. The curative effect difference between the two groups was observed. The correlation between the effect of treatment and the expression of ERβ in cancer tissue was analyzed according to the difference between the two groups.【Results】The effective rate of the prostate cancer patients in the experimental group was significantly higher than that of the control group, the difference was statistically significant (χ2=9.219,P＜0.05). The expression levels of ERβ in cancer tissues were lower in the effective patients of experimental group, the control group and the two groups than those of ineffective patients. The difference was also statistically significant (P＜0.05). According to the expression of ERβ in cancer tissue level and efficacy of single factor logistics regression analysis, the differences were statistically significant (P＜0.05), the maximum likelihood estimates of cancer ERβand OR＜0, which suggested that cancer ER beta expression levels were negatively correlated with the curative effect.【Conclusion】Postoperative chemotherapy combined with endocrine therapy is effective in the treatment of middle and advanced prostate cancer. The effect is negatively correlated with the expression of ER βbeta in cancer tissues.
王进恩,程帆. 中晚期前列腺癌术后化疗联合内分泌治疗的疗效及其与癌组织ERβ表达的相关性[J]. 医学临床研究, 2017, 34(9): 1684-1686,1690.
WANG Jin-en, CHENG Fan. Effect of Postoperative Chemotherapy Combined with Endocrine Therapy on the Expression of ERβ in Cancer Tissues of Advanced Prostate Cancer. JOURNAL OF CLINICAL RESEARCH, 2017, 34(9): 1684-1686,1690.
[1]王婵,董传江,毛峥,等.ERβ真核表达质粒对前列腺癌LNCaP细胞生物学行为的影响及p38信号通路的作用[J].广东医学,2016,37(20):3016-3020. [2]Clarke NW.Management of the spectrum of hormone refractory prostate cancer(EAU Lecture,The 97th Annual Meeting of the Japanese Urological Association)[J].Recept Clin Invest,2017,1(6):3-7. [3]叶木石,李卓,颜赟坤.内分泌治疗联合经尿道前列腺电切术对晚期前列腺癌患者预后的影响[J].广东医学,2016,37(16):2462-2464. [4]廖海球,王正安,李燕,等.调强放疗联合内分泌治疗中晚期前列腺癌的近期疗效观察[J].湖南师范大学学报(医学版),2016,13(4):13-16. [5]Gill D,Gaston D,Bailey E,et al.Efficacy of eplerenone in the management of mineralocorticoid excess in men with metastatic castration-resistant prostate cancer treated with abiraterone without prednisone.[J].Clin Genitourin Cancer,2017,39(23): 1987-1996. [6]赵谊宁,陶陶,张力杰,等.雌激素受体ERα及ERβ与肿瘤关系的研究进展[J].东南大学学报(医学版),2016,35(3):418-422. [7]滕腾,梁颖,任黎刚,等.通幽汤加减联合FOLFOX4方案对晚期前列腺癌患者前血栓状态的影响[J].中国生化药物杂志,2017,37(4):59-62. [8]吴文校,马戟.卡培他滨与多西他赛联合治疗45例激素抵抗性晚期前列腺癌的临床疗效[J].中国医学工程,2015,23(7):26-28. [9]Chen Y,Shundong C,Han L,et al.Establishment of prostate cancer spheres from a prostate cancer cell line after phenethyl isothiocyanate treatment and discovery of androgen-dependent reversible differentiation between sphere and neuroendocrine cells[J].Oncotarget,2016,7(18):26567-26579. [10]陈一鸣,徐仁芳,许贤林,等.血小板淋巴细胞比和中性粒细胞淋巴细胞比对前列腺癌内分泌治疗后早期去势抵抗预测价值的研究[J].中华泌尿外科杂志,2017,38(2):110-114. [11]Yamashita S,Kohjimoto Y,Iguchi T,et al.Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy[J].BMC Urol,2016,16(1):13-20. [12]覃展偶,何书华,张天禹,等.前列腺组织中ERα、ERβ的表达及其意义[J].临床与实验病理学杂志,2010,26(6):701-703. [13]Wang X,Zhang W,Yan Z,et al.Radiosensitization by the investigational NEDD8-activating enzyme inhibitor MLN4924 (pevonedistat) in hormone-resistant prostate cancer cells[J].Oncotarget,2016,7(25):38380-38391. [14]黄玉霞,吴立新,刘杰.内分泌治疗联合去势术治疗晚期前列腺癌56例报告[J].世界最新医学信息文摘,2016,16(81):324.
2017, Vol. 34 
